Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions (SKINDLE)

This study has been completed.
Information provided by (Responsible Party):
Rigel Pharmaceuticals Identifier:
First received: May 9, 2012
Last updated: September 27, 2013
Last verified: September 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2013
  Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)